Literature DB >> 7236525

Erythropoiesis in myelofibrosis with myeloid metaplasia: recognition of different classes of patients by erythrokinetics.

G Barosi, M Cazzola, F Frassoni, E Orlandi, M Stefanelli.   

Abstract

A quantitative assessment of erythropoiesis was performed by means of a mathematical model of iron kinetics in 26 patients with myelofibrosis with myeloid metaplasia (MMM). A direct relationship between total erythropoiesis and red cell volume was revealed. This 'inverse' characteristic of erythropoietic control was the best marker of the proliferative nature of the disease. Three classes of patients were singled out by means of a cluster analysis of the erythrokinetic parameters. In class I (11 patients) the red cell volume was above the predicted normal in all but two patients. Erythropoiesis was sustained at 5--10 times the normal levels with a high degree of ineffective erythropoiesis. A fairly constant absence of erythroid activity over the sacral marrow was demonstrated. In class II most of the 12 patients had a decreased red cell volume. Erythropoiesis was sustained at 2--4 times the normal level with a high degree of peripheral haemolysis. Erythroid activity was recognized over the sacral area in all but two patients. The three patients of class III showed a pattern of erythroid failure and had the worst prognosis. It is suggested that these classes represent separate disease forms of MMM.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7236525     DOI: 10.1111/j.1365-2141.1981.tb08459.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.

Authors:  Yasutaka Fukuda; Marito Araki; Kouji Yamamoto; Soji Morishita; Tadaaki Inano; Kyohei Misawa; Tomonori Ochiai; Yoko Edahiro; Misa Imai; Hajime Yasuda; Akihiko Gotoh; Akimichi Ohsaka; Norio Komatsu
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

2.  Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia.

Authors:  G Barosi; L N Liberato; A Costa; E Ascari
Journal:  Blut       Date:  1989-06

3.  Detection of erythroid hypoplasia in myelofibrosis using erythrokinetic studies.

Authors:  J E Howarth; H M Waters; K Hyde; C G Geary
Journal:  J Clin Pathol       Date:  1989-12       Impact factor: 3.411

4.  Targeting erythroblast-specific apoptosis in experimental anemia.

Authors:  Abhinav Diwan; Andrew G Koesters; Devan Capella; Hartmut Geiger; Theodosia A Kalfa; Gerald W Dorn
Journal:  Apoptosis       Date:  2008-08       Impact factor: 4.677

5.  Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features.

Authors:  G E Verhoef; C De Wolf-Peeters; A Ferrant; S Deprez; P Meeus; M Stul; P Zacheé; J J Cassiman; H Van den Berghe; M A Boogaerts
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

6.  Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival.

Authors:  S Rupoli; L Da Lio; S Sisti; G Campanati; A Salvi; M F Brianzoni; S D'Amico; A Cinciripini; P Leoni
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

7.  Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.

Authors:  Giovanni Barosi; Vittorio Rosti; Elisa Bonetti; Rita Campanelli; Adriana Carolei; Paolo Catarsi; Antonina M Isgrò; Letizia Lupo; Margherita Massa; Valentina Poletto; Gianluca Viarengo; Laura Villani; Umberto Magrini
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.